Tev-Tropin (somatropin (rDNA origin) for injection) was clinically tested and FDA-approved for growth hormone deficiency (GHD), and is manufactured by Savient using recombinant DNA (rDNA) technology.
Teva has begun offering Tev-Tropin to pediatric endocrinologists through its fully owned Gate Pharmaceuticals sales force. Teva will provide a comprehensive patient support program, named Growth Solutions, which will include a patient enrollment program and a call center located within Teva Neuroscience.
Growth Solutions will use customer relationship management technology that is also currently being used to support Copaxone, Teva’s successful multiple sclerosis drug, and its respective Shared Solutions patient support program.
“We welcome any new drug that makes treatment for growth hormone deficiency more accessible for patients and their families,” said Patricia Costa, executive director of the Human Growth Foundation. “Tev-Tropin in concert with the Growth Solutions support program brings more choice and clarity to these families.”